



Contents lists available at ScienceDirect

Tetrahedron

journal homepage: www.elsevier.com/locate/tet

Synthesis of substituted tropones by sequential Rh-catalyzed [5+2] cycloaddition and elimination

Wangze Song^a, Bao-min Xi^{a,b,*}, Ka Yang^a, Weiping Tang^{a,c,*}

^aSchool of Pharmacy, University of Wisconsin, 777 Highland Avenue, Madison, WI 53705-2222, USA

^bGuangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong Province 510515, PR China

^cDepartment of Chemistry, University of Wisconsin, Madison, WI 53706, USA

ARTICLE INFO

Article history:

Received 13 March 2015

Received in revised form 11 April 2015

Accepted 13 April 2015

Available online xxx

Keywords:

Tropones

Cycloaddition

Rhodium

1,4-Enynes

Alkynes

ABSTRACT

Highly substituted tropones are prepared from cycloheptatrienes derived from Rh-catalyzed intermolecular [5+2] cycloaddition of 3-acyloxy-1,4-enynes and propargylic alcohols. The intermolecular [5+2] cycloaddition is highly regioselective for a variety of propargylic alcohols. Elimination of the cycloaddition products afforded various substituted tropones.

© 2015 Elsevier Ltd. All rights reserved.

1. Introduction

Tropones **1** and its derivatives such as tropolone **2** are non-benzenoid seven-membered aromatic compounds. The structures of tropones were first proposed 1940s.¹ To date, over two hundred of naturally occurring tropones derivatives have been identified.² They have broad pharmacological activities ranging from *anti*-bacterial, *anti*-fungal, *anti*-tumor to *anti*-viral activities.³ Many of them have complex structural architectures, such as tropones-containing natural products hainanolidol **3**⁴ and harringtonolide **4**⁵ (Fig. 1).

Numerous methods have been developed for the synthesis of tropones and their derivatives.⁶ Many of them were recently reviewed by us in the context of natural product synthesis.⁷ However, efficient synthesis of highly substituted tropones is a still challenging problem.⁸ For example, only the parent non-substituted tropones was used as the substrate in many of the cycloaddition methods involving tropones including some very recent reports.⁹ We have recently completed the first total synthesis of harringtonolide **4** via a [5+2] cycloaddition¹⁰ of oxidopyrylium




Fig. 1. Tropones, tropolones and tropones-containing natural products.

ion **6** and alkene (Scheme 1).⁵ Although we were able to assemble the carbon skeleton of **4** very efficiently, it took us a number of steps to remove the extra oxygen bridge in **7** for the formation of tropones in target **4**. Clearly, the development of new types of [5+2] cycloadditions is highly desirable.


We have recently reported intra¹¹ and intermolecular¹² Rh-catalyzed [5+2] cycloadditions for the synthesis of highly substituted cycloheptatrienes by using 3-acyloxy-1,4-enyne as a novel 5-carbon component (Scheme 2).¹³ The high degree of unsaturation and the enol ester functionality in cycloaddition product **9** are ideally set up for the synthesis of substituted tropones **10**. We herein report our efforts along this direction for the first time.

Efforts for the conversion of cycloheptatriene product **9** directly to tropones by oxidation were fruitless. Although we were able to


* Corresponding authors. Tel.: +86 20 6164 8549; fax: +86 20 6164 8533 (B.X.); tel.: +1 608 890 1846; fax: +1 608 262 5345 (W.T.); e-mail addresses: xibaomin@sohu.com (B.-min Xi), wtang@pharmacy.wisc.edu (W. Tang).

<http://dx.doi.org/10.1016/j.tet.2015.04.039>

0040-4020/© 2015 Elsevier Ltd. All rights reserved.



Scheme 1. Total synthesis of (±)-harringtonolide.




Scheme 2. Rh-catalyzed intermolecular [5+2] cycloaddition and formation of tropones.

remove the ester group in **9** by reduction or hydrolysis, we could not convert the hydrolyzed products to tropones by oxidative reagents. During the development of the intermolecular [5+2] cycloadditions,¹² we learned that high regioselectivity could be observed when propargylic alcohols **12** were employed as the substrates (Scheme 3). With the hydroxyl group handle in product **13**, we thought we might be able to prepare tropones by elimination reaction instead of oxidation reaction.


Previously, we mainly used the pivalate ester of 3-hydroxy-1,4-enyne as the 5-carbon component for Rh-catalyzed [5+2] cycloadditions.¹² It generally provided higher yields of the product compared to other esters such as acetate or benzoate. We imagine that the acetate in **13** or **14** can be easily hydrolyzed under milder conditions. We first examined the scope of the Rh-catalyzed [5+2] cycloaddition using 3-acyloxy-1,4-enyne **11a** and **11b** with a variety of propargylic alcohols. Ester **11a** was prepared in just one step from commercially available 3-methyl-1-penten-4-yn-3-ol.¹² Ester **11b** is available in three steps from commercially available 1-octyn-3-ol.¹⁴

Product **13a** was prepared as a single isomer (Scheme 3) in the presence of Wilkinson's catalyst. The same condition worked for most of the terminal alkynes. The addition of electron-poor phosphine can improve the yield for products **13c** and **13h**. When internal alkynes are employed, much better yields were obtained for products **13i** and **13j/13j'** under condition b. High regioselectivity was observed for product **13i**, while a ratio of 2:1 was obtained for products **13j** and **13j'**. The R¹ group can be methyl or other alkyl groups, such as *n*-pentyl in **14**. When R¹ was switched phenyl group, the acetate substrate isomerized to conjugated 1,3-enyne **15**¹⁵ under the reaction condition.

We next examined the possibility of synthesizing tropones by eliminating the hydroxyl group in products **13** and **14**. We envisioned that conversion of allylic alcohols **13** or **14** to mesylate **17** followed by based-mediated elimination should yield tetraene intermediate **18**, which could be hydrolyzed to aromatic tropone product **16** via enol intermediate **19** (Scheme 4). Indeed, a three-step sequence converted **13a** to tropone **16a** in a 61% isolated yield. We also tried to treat mesylate intermediate **17a** with





a) RhCl(PPh₃)₃ (5 mol%), CHCl₃, 65 °C
b) [Rh(COD)Cl]₂ (5 mol%), *p*-(CF₃C₆H₄)₃P, CHCl₃, 65 °C



Scheme 3. Synthesis of substituted cycloheptatrienes.

potassium carbonate in methanol to complete both elimination and hydrolysis in one step. However, the yield was much lower using the two step sequence.

We then examined the scope of the three-step sequence. A variety of disubstituted tropones could be prepared from the corresponding cycloheptatrienes. Tropones **16d** and **16f** were obtained in lower yields from substrates bearing a benzylic or a tertiary alcohol, respectively. The TBS-protected primary alcohol in substrate **13h** can be tolerated and tropone **16h** was prepared in a 56% isolated yield. Trisubstituted tropone **16i** was prepared from the corresponding alcohol **13i** in a 63% isolated yield. Trisubstituted tropones **16j** and **16j'** could be isolated in 47% and 24% yields, respectively, from a mixture of non-separable alcohols **13j** and **13j'**. Cycloheptatriene **14** was also converted to tropone **20** under the same condition.




^a. Isolated yield after three steps.

Scheme 4. Synthesis of substituted tropones.

We further functionalized tropone products **16b**, **16d**, and **16e** to amino-tropones **21** (Scheme 5). The amino group was introduced to the α' -position of tropones by treating them with hydrazine following literature procedures.^{3a} Since the α -position is blocked by methyl substituent, regioselectivity is not a concern for the amination reaction.

We also explored the [4+2] cycloaddition between tropone **16b** and anhydride **22**. Under thermal conditions, cycloaddition product **23** was obtained in high regio- and diastereoselectivity. The less substituted diene in tropone **16b** selectively reacted with the dienophile and afforded only the *endo*-product.

In summary, we have developed an efficient sequence to convert products derived from Rh-catalyzed [5+2] cycloaddition of 3-acyloxy-1-enynes and alkynes to substituted tropones. High regioselectivity was observed for all terminal alkynes in the Rh-catalyzed [5+2] cycloaddition. For internal alkynes, high regioselectivity could also be obtained when there were two electronically differentiated substituents on the two termini of the internal alkynes. Various di- and tri-substituted tropones were synthesized efficiently from the cycloheptatriene cycloaddition product by a three-step mesylation, elimination and hydrolysis sequence.



Scheme 5. Amination and cycloaddition of substituted tropones.

2. Experimental section

Esters **11a** and **11b** were prepared from the corresponding alcohols by esterification reactions following our previously reported procedures.^{12,14}

2.1. General procedures for the Rh-catalyzed intermolecular [5+2] cycloaddition

Method A: To a flask containing 1,4-enyne (1 mmol) and alkyne (2 mmol) was added RhCl(PPh₃)₃ (5 mol %) and chloroform (0.4 M). The flask was flushed with argon and allowed to stir at 65 °C. The reaction was monitored by TLC until the 1,4-enyne was completely consumed (approximately 12 h). The solvent was evaporated and the resulting residue was purified via flash chromatography on silica gel using ethyl acetate and hexanes to yield [5+2] cycloaddition products.

Method B: To a flask containing 1,4-enyne (1 mmol) and alkyne (2 mmol) was added [Rh(COD)Cl]₂ (5 mol %), tris[4-(trifluoromethyl)phenyl] phosphine (30 mol %) and chloroform (0.4 M). The flask was flushed with argon and allowed to stir at 65 °C. The reaction was monitored by TLC until the 1,4-enyne was completely consumed (approximately 12 h). The solvent was evaporated and the resulting residue was purified via flash chromatography on silica gel using ethyl acetate and hexanes to yield [5+2] cycloaddition products.

2.2. 4-(1-Hydroxyethyl)-7-methylcyclohepta-1,3,6-trien-1-yl acetate (**13a**)

Oil. Method A, 66% yield. ¹H NMR (500Mz, CDCl₃) δ 6.22 (d, *J*=6.5 Hz, 1H), 6.07 (d, *J*=6.5 Hz, 1H), 5.25 (t, *J*=7.5 Hz, 1H), 4.44 (q, *J*=6.5 Hz, 1H), 2.58–2.54 (m, 1H), 2.28–2.24 (m, 1H), 2.21 (s, 3H), 1.78 (s, 3H), 1.31 (d, *J*=8.5 Hz, 3H); ¹³C NMR (100Mz, CDCl₃) δ 169.6, 151.9, 142.1, 130.8, 120.8, 119.5, 117.5, 71.1, 27.9, 23.6, 21.0, 17.9. IR (film): 2926, 1730, 1637, 1440, 1370, 1218, 1056, 830 cm⁻¹. HRMS (ESI) *m/z* calcd. For C₁₂H₁₆O₃ (M+Na)⁺ 231.0997, found 231.0993.

2.3. 4-(1-Hydroxyhexyl)-7-methylcyclohepta-1,3,6-trien-1-yl acetate (**13b**)

Oil. Method A, 71% yield. ¹H NMR (500Mz, CDCl₃) δ 6.22 (d, *J*=6.5 Hz, 1H), 6.02 (d, *J*=6.5 Hz, 1H), 5.22 (t, *J*=7.0 Hz, 1H), 4.22–4.19

(m, 1H), 2.58–2.54 (m, 1H), 2.24–2.20 (m, 1H), 2.20 (s, 3H), 1.78 (s, 3H), 1.72 (s, 1H), 1.57–1.53 (m, 2H), 1.35–1.24 (m, 6H), 0.87 (t, $J=7.0$ Hz, 3H); ^{13}C NMR (100Mz, CDCl_3) δ 169.6, 151.8, 141.0, 130.7, 120.8, 119.4, 118.5, 75.5, 37.0, 31.9, 27.7, 25.7, 22.7, 21.0, 17.9, 14.2. IR (film): 2930, 1728, 1637, 1370, 1210, 1062, 834, 777 cm^{-1} . HRMS (ESI) m/z calcd. For $\text{C}_{16}\text{H}_{24}\text{O}_3$ ($\text{M}+\text{Na}$) $^{+}$ 287.1623, found 287.1618.

2.4. 4-(1-Hydroxy-3-phenylpropyl)-7-methylcyclohepta-1,3,6-trien-1-yl acetate (13c)

Oil. Method A, 55% yield. Method B, 69% yield. ^1H NMR (400Mz, CDCl_3) δ 7.30–7.26 (m, 2H), 7.20–7.16 (m, 3H), 6.22 (d, $J=6.4$ Hz, 1H), 6.05 (d, $J=6.4$ Hz, 1H), 5.24 (t, $J=6.0$ Hz, 1H), 4.25–4.23 (m, 1H), 2.70–2.62 (m, 2H), 2.60–2.57 (m, 1H), 2.24–2.19 (m, 4H), 1.91–1.84 (m, 2H), 1.79 (s, 3H), 1.67 (s, 1H); ^{13}C NMR (100Mz, CDCl_3) δ 169.6, 152.0, 142.0, 140.5, 130.9, 128.68, 128.66, 126.1, 120.8, 119.4, 118.8, 74.8, 39.7, 32.4, 27.7, 21.0, 17.9. IR (film): 3027, 2923, 1749, 1637, 1454, 1369, 1213, 1120, 1056, 833 cm^{-1} . HRMS (ESI) m/z calcd. For $\text{C}_{19}\text{H}_{22}\text{O}_3$ ($\text{M}+\text{Na}$) $^{+}$ 321.1461, found 321.1461.

2.5. 4-(Hydroxy(phenyl)methyl)-7-methylcyclohepta-1,3,6-trien-1-yl acetate (13d)

Oil. Method A, 68% yield. ^1H NMR (400Mz, CDCl_3) δ 7.38–7.25 (m, 5H), 6.25 (s, 2H), 5.34 (s, 1H), 5.00 (t, $J=7.2$ Hz, 1H), 2.41–2.36 (m, 1H), 2.28–2.23 (m, 1H), 2.18 (s, 3H), 1.73 (s, 3H); ^{13}C NMR (100Mz, CDCl_3) δ 169.6, 152.0, 142.4, 140.3, 130.7, 128.6, 128.0, 126.9, 121.7, 119.3, 119.1, 77.1, 28.5, 21.0, 17.9. IR (film): 2935, 1750, 1632, 1441, 1142, 1060, 924, 770, 697 cm^{-1} . HRMS (ESI) m/z calcd. For $\text{C}_{17}\text{H}_{18}\text{O}_3$ ($\text{M}+\text{Na}$) $^{+}$ 293.1154, found 293.1151.

2.6. 4-(1-Hydroxy-2,2-dimethylpropyl)-7-methylcyclohepta-1,3,6-trien-1-yl acetate (13e)

Oil. Method A, 73% yield. ^1H NMR (500Mz, CDCl_3) δ 6.22 (d, $J=6.5$ Hz, 1H), 6.00 (d, $J=6.5$ Hz, 1H), 5.26 (t, $J=7.5$ Hz, 1H), 3.97 (s, 1H), 2.68–2.64 (m, 1H), 2.20–2.16 (m, 4H), 1.80 (s, 3H), 1.70 (s, 1H), 0.93 (s, 9H); ^{13}C NMR (125Mz, CDCl_3) δ 169.6, 151.7, 139.0, 131.0, 121.1, 120.4, 119.5, 83.6, 36.0, 26.5, 25.6, 25.5, 21.0, 17.9. IR (film): 2981, 2874, 2341, 1747, 1637, 1480, 1266, 1005, 896 cm^{-1} . HRMS (ESI) m/z calcd. For $\text{C}_{15}\text{H}_{22}\text{O}_3$ ($\text{M}+\text{Na}$) $^{+}$ 273.1461, found 273.1460.

2.7. 4-(2-Hydroxypropan-2-yl)-7-methylcyclohepta-1,3,6-trien-1-yl acetate (13f)

Oil. Method A, 62% yield. ^1H NMR (400Mz, CDCl_3) δ 6.25 (d, $J=6.8$ Hz, 1H), 6.17 (d, $J=6.4$ Hz, 1H), 5.26 (t, $J=7.2$ Hz, 1H), 2.42 (d, $J=7.6$ Hz, 2H), 2.21 (s, 3H), 1.78 (s, 3H), 1.41 (s, 6H); ^{13}C NMR (100Mz, CDCl_3) δ 169.7, 151.4, 145.4, 130.6, 120.9, 119.7, 115.5, 73.0, 30.0, 29.9, 21.0, 17.8. IR (film): 3450, 2979, 1740, 1637, 1438, 1367, 1215, 1115, 1062, 957 cm^{-1} . HRMS (ESI) m/z calcd. For $\text{C}_{13}\text{H}_{18}\text{O}_3$ ($\text{M}+\text{Na}$) $^{+}$ 245.1148, found 245.1153.

2.8. 4-(1-Hydroxy-2-methylpentyl)-7-methylcyclohepta-1,3,6-trien-1-yl acetate (13g)

Oil. Method A, 64% yield (dr 1:1). ^1H NMR (500Mz, CDCl_3) δ 6.23 (dd, $J=9.0$, 6.0 Hz, 1H), 6.02 (dd, $J=15.0$, 6.0 Hz, 1H), 5.23–5.21 (m, 1H), 4.01 (dd, $J=45.5$, 6.0 Hz, 1H), 2.48–2.44 (m, 1H), 2.30–2.27 (m, 1H), 2.21 (s, 3H), 1.78 (s, 3H), 1.67–1.65 (m, 1H), 1.34–1.25 (m, 4H), 1.10–1.07 (m, 1H), 0.92–0.85 (m, 5H), 0.79 (d, $J=7.0$ Hz, 1H); ^{13}C NMR (100Mz, CDCl_3) δ 169.6, 166.6, 151.8, 151.6, 140.3, 140.2, 130.9, 130.8, 121.0, 120.7, 119.8, 119.5, 119.4, 119.1, 80.4, 79.2, 37.6, 37.3, 36.1, 34.2, 27.9, 21.0, 20.5, 20.4, 17.907, 17.899, 16.7, 14.6, 14.5, 14.3. IR (film): 3426, 2922, 1727, 1456, 1371, 1216, 1123, 1037, 924 cm^{-1} .

HRMS (ESI) m/z calcd. For $\text{C}_{16}\text{H}_{24}\text{O}_3$ ($\text{M}+\text{Na}$) $^{+}$ 287.1617, found 287.1615.

2.9. 4-2-((*tert*-Butyldimethylsilyl)oxy)-1-hydroxyethyl)-7-methylcyclohepta-1,3,6-trien-1-yl acetate (13h)

Oil. Method B, 90% yield. ^1H NMR (500Mz, CDCl_3) δ 6.26 (d, $J=6.5$ Hz, 1H), 6.14 (d, $J=6.5$ Hz, 1H), 5.21 (t, $J=7.0$ Hz, 1H), 4.30 (d, $J=8.5$ Hz, 1H), 3.63 (dd, $J=10.0$, 3.5 Hz, 1H), 3.39 (dd, $J=10.0$, 8.5 Hz, 1H), 2.76 (d, $J=2.5$ Hz, 1H), 2.59–2.55 (m, 1H), 2.21 (s, 3H), 2.17–2.13 (m, 1H), 1.78 (s, 3H), 0.90 (s, 9H), 0.07 (s, 6H); ^{13}C NMR (125Mz, CDCl_3) δ 169.6, 152.1, 135.6, 131.0, 119.8, 119.7, 119.6, 75.2, 67.3, 28.0, 26.1, 21.0, 18.5, 17.9, –5.0, –5.1. IR (film): 2970, 2858, 2349, 1738, 1436, 1374, 1110, 1060, 834 cm^{-1} . HRMS (ESI) m/z calcd. For $\text{C}_{18}\text{H}_{30}\text{O}_4\text{Si}$ ($\text{M}+\text{Na}$) $^{+}$ 361.1805, found 361.1802.

2.10. 4-(Hydroxymethyl)-3,7-dimethylcyclohepta-1,3,6-trien-1-yl acetate (13i)

Oil. Method B, 76% yield. ^1H NMR (500Mz, CDCl_3) δ 6.18 (s, 1H), 5.40 (t, $J=9.0$ Hz, 1H), 4.23 (s, 2H), 2.44 (d, $J=7.5$ Hz, 2H), 2.20 (s, 3H), 2.06–2.01 (m, 1H), 1.87 (s, 3H), 1.76 (s, 3H); ^{13}C NMR (100Mz, CDCl_3) δ 169.5, 151.0, 130.2, 129.9, 127.4, 124.7, 122.3, 62.8, 30.4, 20.9, 17.8, 17.6. IR (film): 3405, 2950, 1752, 1637, 1321, 1131, 1061, 1016, 873 cm^{-1} . HRMS (ESI) m/z calcd. For $\text{C}_{12}\text{H}_{16}\text{O}_3$ ($\text{M}+\text{Na}$) $^{+}$ 231.0991, found 231.0989.

2.11. 3-(((*tert*-Butyldimethylsilyl)oxy)methyl)-4-(hydroxymethyl)-7-methylcyclohepta-1,3,6-trien-1-yl acetate (13j and 13j')

Oil. Method B, 79% yield (2:1) mixture. Major ^1H NMR (500Mz, CDCl_3) δ 6.29 (s, 1H), 5.34 (t, $J=7.5$ Hz, 1H), 4.36–4.34 (m, 2H), 4.30–4.26 (m, 2H), 2.40 (s, 2H), 2.20 (s, 3H), 1.77 (s, 3H), 0.89 (s, 9H), 0.08 (s, 6H); Major ^{13}C NMR (100Mz, CDCl_3) δ 169.5, 151.7, 131.8, 130.2, 122.3, 120.1, 63.7, 63.5, 31.7, 26.0, 21.0, 18.5, 17.6, –5.0. IR (film): 2930, 2858, 1728, 1472, 1370, 1135, 1062, 834 cm^{-1} . HRMS (ESI) m/z calcd. For $\text{C}_{18}\text{H}_{30}\text{O}_4\text{Si}$ ($\text{M}+\text{Na}$) $^{+}$ 361.1805, found 361.1808.

2.12. 4-(Hydroxymethyl)-7-pentylcyclohepta-1,3,6-trien-1-yl acetate (14)

Oil. Method A, 62% yield. ^1H NMR (500Mz, CDCl_3) δ 6.26 (d, $J=6.0$ Hz, 1H), 6.06 (d, $J=6.5$ Hz, 1H), 5.28 (t, $J=7.0$ Hz, 1H), 4.24 (s, 2H), 2.42 (d, $J=7.5$ Hz, 2H), 2.19 (s, 3H), 2.08 (t, $J=8.0$ Hz, 2H), 1.68 (s, 1H), 1.38–1.32 (m, 2H), 1.29–1.24 (m, 2H), 1.20–1.16 (m, 2H), 0.85 (t, $J=7.5$ Hz, 3H); ^{13}C NMR (125Mz, CDCl_3) δ 169.7, 151.6, 137.9, 135.5, 120.24, 120.15, 118.3, 66.2, 32.2, 31.7, 29.1, 29.0, 22.6, 21.0, 14.2. IR (film): 3431, 2928, 1750, 1436, 1364, 1122, 1020, 928 cm^{-1} . HRMS (ESI) m/z calcd. For $\text{C}_{15}\text{H}_{22}\text{O}_3$ ($\text{M}+\text{Na}$) $^{+}$ 273.1467, found 273.1471.

2.13. General procedures for the synthesis of tropones from cycloheptatrienes

To a solution of the cycloheptatriene substrate (0.2 mmol) in dry dichloromethane (4 mL) was added triethylamine (85 μL) and MsCl (31 μL) at -78°C . The reaction was warmed to room temperature and stirred for 1 h. The solution was quenched with saturated aqueous NaHCO_3 (10 mL) solution and extracted with dichloromethane (3×10 mL). The combined organic layers were washed with brine, dried with Na_2SO_4 , concentrated under vacuum to give the crude mesylation product.

To a solution of the crude mesylation product in dry THF (4 mL) was added DBU (44 μL) at room temperature. After stirring at this temperature for 10–30 min, it was concentrated to give the crude tetraene product. To a solution of this crude product in MeOH

(4 mL) was added K_2CO_3 (13 mg) at room temperature. After stirring at this temperature for 5–10 min, the product was concentrated under vacuum. The residue was purified by flash chromatography on silica gel using ethyl acetate and hexanes to give the final tropone product.

2.14. 5-Ethyl-2-methylcyclohepta-2,4,6-trienone (16a)

Oil. 18 mg, 61% yield. 1H NMR (500Mz, $CDCl_3$) δ 7.25 (d, $J=9.5$ Hz, 1H), 7.04 (s, 2H), 6.78 (d, $J=9.5$ Hz, 1H), 2.55 (q, $J=7.5$ Hz, 2H), 2.25 (s, 3H), 1.21 (t, $J=7.5$ Hz, 3H); ^{13}C NMR (100Mz, $CDCl_3$) δ 187.2, 150.1, 149.4, 139.6, 138.5, 136.0, 131.2, 33.0, 22.7, 15.3. IR (film): 3417, 3055, 2854, 1728, 1573, 1266, 1080, 957 cm^{-1} . HRMS (ESI) m/z calcd. For $C_{10}H_{12}O$ (M+Na) $^+$ 171.0780, found 171.0779.

2.15. 5-Hexyl-2-methylcyclohepta-2,4,6-trienone (16b)

Oil. 28 mg, 67% yield. 1H NMR (500Mz, $CDCl_3$) δ 7.24 (d, $J=9.0$ Hz, 1H), 7.03 (s, 2H), 6.76 (d, $J=9.0$ Hz, 1H), 2.49 (t, $J=7.5$ Hz, 2H), 2.25 (s, 3H), 1.57–1.55 (m, 2H), 1.34–1.27 (m, 6H), 0.88 (t, $J=7.0$ Hz, 3H); ^{13}C NMR (100Mz, $CDCl_3$) δ 187.2, 150.1, 148.2, 139.5, 138.7, 135.9, 132.0, 40.0, 31.8, 31.0, 29.0, 22.8, 22.7, 14.3. IR (film): 3040, 2925, 1737, 1581, 1664, 1360, 1220, 962 cm^{-1} . HRMS (ESI) m/z calcd. For $C_{14}H_{20}O$ (M+Na) $^+$ 227.1412, found 227.1416.

2.16. 2-Methyl-5-(3-phenylpropyl)cyclohepta-2,4,6-trienone (16c)

Oil. 29 mg, 60% yield. 1H NMR (400Mz, $CDCl_3$) δ 7.31–7.29 (m, 2H), 7.24–7.21 (m, 2H), 7.19–7.16 (m, 2H), 7.02 (s, 2H), 6.76 (d, $J=9.2$ Hz, 1H), 2.66 (t, $J=7.6$ Hz, 2H), 2.53 (t, $J=9.5$ Hz, 2H), 2.27 (s, 3H), 1.96–1.88 (m, 2H); ^{13}C NMR (100Mz, $CDCl_3$) δ 187.2, 150.4, 147.5, 141.7, 139.6, 138.5, 135.7, 132.2, 128.7, 128.6, 126.3, 39.4, 35.4, 32.5, 22.7. IR (film): 3053, 2927, 2858, 1730, 1573, 1456, 1265, 1097, 733, 700 cm^{-1} . HRMS (ESI) m/z calcd. For $C_{17}H_{18}O$ (M+H) $^+$ 239.1430, found 239.1436.

2.17. 5-Benzyl-2-methylcyclohepta-2,4,6-trienone (16d)

Oil. 21 mg, 51% yield. 1H NMR (500Mz, $CDCl_3$) δ 7.33–7.30 (m, 3H), 7.26–7.24 (m, 1H), 7.17–7.15 (m, 2H), 6.99 (s, 2H), 6.81 (d, $J=9.0$ Hz, 1H), 3.85 (s, 2H), 2.25 (s, 3H); ^{13}C NMR (100Mz, $CDCl_3$) δ 187.1, 150.6, 146.0, 139.5, 139.1, 138.5, 135.6, 132.7, 129.2, 129.1, 127.1, 45.5, 22.7. IR (film): 3055, 2987, 2361, 1726, 1575, 1422, 1265, 896. cm^{-1} . HRMS (ESI) m/z calcd. For $C_{15}H_{14}O$ (M+Na) $^+$ 233.0937, found 233.0945.

2.18. 2-Methyl-5-neopentylcyclohepta-2,4,6-trienone (16e)

Oil. 28 mg, 72% yield. 1H NMR (500Mz, $CDCl_3$) δ 7.26 (d, $J=9.0$ Hz, 1H), 7.00 (s, 2H), 6.72 (d, $J=9.5$ Hz, 1H), 2.41 (s, 2H), 2.27 (s, 3H), 0.93 (s, 9H); ^{13}C NMR (100Mz, $CDCl_3$) δ 187.2, 150.5, 145.5, 140.5, 138.3, 135.4, 134.3, 53.6, 32.8, 29.6, 22.7. IR (film): 3060, 2964, 1730, 1587, 1403, 1264, 1080, 1026 cm^{-1} . HRMS (ESI) m/z calcd. For $C_{13}H_{18}O$ (M+Na) $^+$ 213.1255, found 213.1259.

2.19. 5-Isopropyl-2-methylcyclohepta-2,4,6-trienone (16f)

Oil. 14 mg, 42% yield. All spectra data are in accordance with literature.¹⁶

2.20. 2-Methyl-5-(2-methylpentyl)cyclohepta-2,4,6-trienone (16g)

Oil. 31 mg, 75% yield. 1H NMR (400Mz, $CDCl_3$) δ 7.24 (d, $J=9.2$ Hz, 1H), 7.05–6.98 (m, 2H), 6.73 (d, $J=9.2$ Hz, 1H), 2.55–2.51 (m, 1H),

2.25 (s, 3H), 2.25–2.20 (m, 1H), 1.72–1.67 (m, 1H), 1.41–1.25 (m, 3H), 1.19–1.13 (m, 1H), 0.90–0.85 (m, 6H); ^{13}C NMR (100Mz, $CDCl_3$) δ 187.2, 150.2, 147.1, 139.2, 139.0, 135.7, 133.0, 47.6, 39.1, 34.5, 22.7, 20.3, 19.4, 14.5. IR (film): 2455, 2360, 2254, 1737, 1625, 1565, 1421, 1230, 1095, 904. cm^{-1} . HRMS (ESI) m/z calcd. For $C_{14}H_{20}O$ (M+Na) $^+$ 227.1406, found 227.1409.

2.21. 5-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-2-methylcyclohepta-2,4,6-trienone (16h)

Oil. 32 mg, 56% yield. 1H NMR (500Mz, $CDCl_3$) δ 7.27 (d, $J=9.5$ Hz, 1H), 7.19–7.03 (m, 2H), 6.83 (d, $J=9.0$ Hz, 1H), 3.83 (t, $J=6.0$ Hz, 2H), 2.71 (t, $J=6.5$ Hz, 2H), 2.28 (s, 3H), 0.86 (s, 9H), 0.01 (s, 6H); ^{13}C NMR (100Mz, $CDCl_3$) δ 187.1, 150.7, 145.0, 139.20, 139.18, 135.6, 133.4, 63.6, 43.1, 26.1, 22.7, 18.5, –5.2. IR (film): 2953, 2895, 1730, 1631, 1577, 1374, 1254, 1095. cm^{-1} . HRMS (ESI) m/z calcd. For $C_{16}H_{26}O_2Si$ (M+Na) $^+$ 301.1594, found 301.1597.

2.22. 2,5,6-Trimethylcyclohepta-2,4,6-trienone (16i)

Oil. 19 mg, 63% yield. 1H NMR (500Mz, $CDCl_3$) δ 7.14–7.11 (m, 2H), 6.81 (d, $J=9.5$ Hz, 1H), 2.27 (s, 3H), 2.25 (s, 3H), 2.22 (s, 3H); ^{13}C NMR (100Mz, $CDCl_3$) δ 186.3, 149.0, 147.1, 144.1, 140.2, 134.9, 132.1, 26.0, 25.5, 22.1. IR (film): 2923, 2855, 1738, 1566, 1372, 1216, 950, 894, 713 cm^{-1} . HRMS (ESI) m/z calcd. For $C_{10}H_{12}O$ (M+H) $^+$ 149.0960, found 149.0966.

2.23. 6-(((tert-Butyldimethylsilyl)oxy)methyl)-2,5-dimethylcyclohepta-2,4,6-trienone (16j)

Oil. 27 mg, 47% yield. 1H NMR (500Mz, $CDCl_3$) δ 7.28 (d, $J=9.5$ Hz, 1H), 7.14 (d, $J=10.0$ Hz, 1H), 7.07 (s, 1H), 4.53 (s, 2H), 2.25 (s, 6H), 0.94 (s, 9H), 0.11 (s, 6H); ^{13}C NMR (100Mz, $CDCl_3$) δ 186.5, 150.0, 145.3, 145.0, 140.8, 134.9, 129.1, 65.2, 26.15, 26.11, 23.2, 22.3, 18.6, –5.1. IR (film): 3055, 2955, 1729, 1626, 1265, 1063, 1017, 838. cm^{-1} . HRMS (ESI) m/z calcd. For $C_{16}H_{26}O_2Si$ (M+Na) $^+$ 301.1594, found 301.1600.

2.24. 5-(((tert-Butyldimethylsilyl)oxy)methyl)-2,6-dimethylcyclohepta-2,4,6-trienone (16j')

Oil. 13 mg, 24% yield. 1H NMR (500Mz, $CDCl_3$) δ 7.36 (s, 1H), 7.14 (d, $J=9.0$ Hz, 1H), 6.77 (d, $J=9.5$ Hz, 1H), 4.53 (s, 2H), 2.24 (s, 6H), 0.93 (s, 9H), 0.11 (s, 6H); ^{13}C NMR (100Mz, $CDCl_3$) δ 187.1, 149.4, 147.8, 142.0, 136.5, 134.8, 132.9, 66.5, 26.1, 22.7, 22.1, 18.6, –5.0. IR (film): 3055, 2954, 2858, 1738, 1625, 1265, 1177, 1060, 940. cm^{-1} . HRMS (ESI) m/z calcd. For $C_{16}H_{26}O_2Si$ (M+Na) $^+$ 301.1594, found 301.1601.

2.25. 5-Methyl-2-pentylcyclohepta-2,4,6-trienone (20)

Oil. 23 mg, 60% yield. 1H NMR (400Mz, $CDCl_3$) δ 7.12 (d, $J=9.2$ Hz, 1H), 6.99 (s, 2H), 6.80 (d, $J=9.2$ Hz, 1H), 2.62–2.58 (m, 2H), 2.30 (s, 3H), 1.56–1.50 (m, 2H), 1.36–1.31 (m, 4H), 0.88 (t, $J=6.8$ Hz, 3H); ^{13}C NMR (100Mz, $CDCl_3$) δ 186.8, 153.9, 143.3, 139.7, 139.0, 135.3, 132.3, 35.4, 32.0, 28.8, 25.8, 22.8, 14.2. IR (film): 2955, 2925, 1729, 1633, 1574, 1462, 1190, 1040, 844. cm^{-1} . HRMS (ESI) m/z calcd. For $C_{13}H_{18}O$ (M+Na) $^+$ 213.1249, found 213.1256.

2.26. General procedures for the amination of tropones

To a solution of α -methyl-tropone (0.1 mmol) in EtOH (0.5 mL) was added 65% hydrazine monohydrate (0.12 mL). The solution was allowed to stir at 60 °C until all starting material was consumed by monitoring the reaction by TLC (~2h). The reaction was concentrated under vacuum and then taken up in EtOAc (4 mL) and

washed with H₂O (3×4 mL). The organic layer was then washed with brine, dried over Na₂SO₄, filtered and concentrated under vacuum. The crude residue was purified by flash column chromatography on silica gel using ethyl acetate and hexanes to provide the desired α -amino-tropones.

2.27. 2-Amino-4-hexyl-7-methylcyclohepta-2,4,6-trienone (21a)

Oil. 17 mg, 79% yield. ¹H NMR (500Mz, CDCl₃) δ 7.37 (d, J =9.5 Hz, 1H), 6.80 (s, 1H), 6.57 (d, J =10.0 Hz, 1H), 5.80 (br s, 2H), 2.54–2.51 (m, 2H), 2.40 (s, 3H), 1.62–1.57 (m, 2H), 1.35–1.25 (m, 6H), 0.89 (t, J =6.5 Hz, 3H); ¹³C NMR (125Mz, CDCl₃) δ 175.2, 154.1, 150.5, 139.0, 137.5, 123.9, 115.3, 41.2, 32.1, 31.9, 29.1, 23.4, 22.8, 14.3. IR (film): 3055, 2987, 1730, 1530, 1422, 1265, 839. cm⁻¹. HRMS (ESI) m/z calcd. For C₁₄H₂₁NO (M+Na)⁺ 242.1515, found 242.1584.

2.28. 2-Amino-4-benzyl-7-methylcyclohepta-2,4,6-trienone (21b)

Oil. 19 mg, 85% yield. ¹H NMR (500Mz, CDCl₃) δ 7.39 (d, J =10.0 Hz, 1H), 7.32–7.29 (m, 2H), 7.24–7.22 (m, 1H), 7.18 (d, J =7.0 Hz, 2H), 6.76 (s, 1H), 6.62 (d, J =10.0 Hz, 1H), 5.76 (br s, 2H), 3.90 (s, 2H), 2.39 (s, 3H); ¹³C NMR (125Mz, CDCl₃) δ 175.5, 153.9, 148.0, 140.3, 139.5, 137.4, 129.1, 128.9, 126.9, 124.5, 115.3, 46.5, 23.4. IR (film): 3319, 3282, 2382, 1728, 1609, 1521, 1276, 969, 740. cm⁻¹. HRMS (ESI) m/z calcd. For C₁₅H₁₅NO (M+Na)⁺ 248.1045, found 248.1048.

2.29. 2-Amino-4-(tert-butyl)-7-methylcyclohepta-2,4,6-trienone (21c)

Oil. 16 mg, 79% yield. ¹H NMR (500Mz, CDCl₃) δ 7.37 (d, J =10.0 Hz, 1H), 6.76 (s, 1H), 6.52 (d, J =10.0 Hz, 1H), 5.79 (br s, 2H), 2.46 (s, 2H), 2.41 (s, 3H), 0.94 (s, 9H); ¹³C NMR (125Mz, CDCl₃) δ 175.2, 153.3, 147.3, 139.2, 136.8, 126.0, 117.3, 54.8, 32.8, 29.8, 23.4. IR (film): 3419, 3281, 2952, 1730, 1605, 1524, 1424, 1363, 1163, 962, 829 cm⁻¹. HRMS (ESI) m/z calcd. For C₁₃H₁₉NO (M+Na)⁺ 228.1358, found 228.1365.

2.30. Procedure for the synthesis of 23 via [4+2] cycloaddition

To a solution of tropone **16b** (0.06 mmol) in xylene (0.3 mL) was added furan-2,5-dione (29.5 mg). The solution was allowed to stir at 120 °C overnight. The reaction was concentrated under vacuum and purified by flash column chromatography on silica gel using ethyl acetate and hexanes to provide the desired cycloaddition product in 65% yield.

2.31. 9-Hexyl-6-methyl-3a,4,8,8a-tetrahydro-1H-4,8-ethenocyclohepta[c]furan-1,3,5-trione (23)

Oil. 12 mg, 65% yield. ¹H NMR (400Mz, CDCl₃) δ 6.98 (d, J =6.8 Hz, 1H), 5.79 (d, J =6.0 Hz, 1H), 3.99 (dd, J =6.0, 1.2 Hz, 1H), 3.69 (dd,

J =7.2, 2.0 Hz, 1H), 3.60–3.58 (m, 1H), 3.53 (dd, J =7.2, 1.2 Hz, 1H), 2.12–2.08 (m, 2H), 1.76 (s, 3H), 1.37–1.33 (m, 2H), 1.30–1.23 (m, 6H), 0.87 (t, J =9.6 Hz, 3H); ¹³C NMR (125Mz, CDCl₃) δ 193.4, 171.0, 152.5, 144.2, 137.7, 118.1, 53.9, 47.9, 43.1, 42.2, 36.7, 31.7, 28.9, 26.8, 22.8, 18.4, 14.3. IR (film): 3055, 2930, 2359, 1785, 1674, 1265, 1076, 928, 832 cm⁻¹. HRMS (ESI) m/z calcd. For C₁₈H₂₂O₄ (M+Na)⁺ 325.1410, found 325.1424.

Acknowledgements

W. T. thanks University of Wisconsin and National Institute of Health (R01GM088285) for funding. B.-m. Xi thanks Southern Medical University for funding.

Supplementary data

Supplementary data (NMR spectra for all new compounds.) related to this article can be found at <http://dx.doi.org/10.1016/j.tet.2015.04.039>.

References and notes

- (a) Dewar, M. J. S. *Nature* **1945**, 155, 50; (b) Dewar, M. J. S. *Nature* **1945**, 155, 141.
- (a) Zhao, J. *Curr. Med. Chem.* **2007**, 14, 2597; (b) Bentley, R. *Nat. Prod. Rep.* **2008**, 25, 118.
- (a) Ononye, S. N.; VanHeyst, M. D.; Oblak, E. Z.; Zhou, W.; Ammar, M.; Anderson, A. C.; Wright, D. L. *ACS Med. Chem. Lett.* **2013**, 4, 757; (b) Day, J. A.; Cohen, S. M. *J. Med. Chem.* **2013**, 56, 7997; (c) Hirsch, D. R.; Cox, G.; D'Erasmo, M. P.; Shakya, T.; Meck, C.; Mohd, N.; Wright, G. D.; Murelli, R. P. *Bioorg. Med. Chem. Lett.* **2014**, 24, 4943.
- Frey, B.; Wells, A. P.; Rogers, D. H.; Mander, L. N. *J. Am. Chem. Soc.* **1998**, 120, 1914.
- Zhang, M.; Liu, N.; Tang, W. *J. Am. Chem. Soc.* **2013**, 135, 12434.
- (a) Graening, T.; Schmalz, H. G. *Angew. Chem., Int. Ed.* **2004**, 43, 3230; (b) Battiste, M. A.; Pelphrey, P. M.; Wright, D. L. *Chem.—Eur. J.* **2006**, 12, 3438; (c) Abdelkafi, H.; Nay, B. *Nat. Prod. Rep.* **2012**, 29, 845; (d) Meck, C.; D'Erasmo, M. P.; Hirsch, D. R.; Murelli, R. P. *Med. Chem. Comm.* **2014**, 5, 842.
- Liu, N.; Song, W.; Schienebeck, C. M.; Zhang, M.; Tang, W. *Tetrahedron* **2014**, 70, 9281.
- (a) Meck, C.; Mohd, N.; Murelli, R. P. *Org. Lett.* **2012**, 14, 5988; (b) Williams, Y. D.; Meck, C.; Mohd, N.; Murelli, R. P. *J. Org. Chem.* **2013**, 78, 11707.
- (a) Houk, K. N.; Woodward, R. B. *J. Am. Chem. Soc.* **1970**, 92, 4145; (b) Houk, K. N.; Luskus, L. J.; Bhacca, N. S. *J. Am. Chem. Soc.* **1970**, 92, 6392; (c) Noble, W. J. L.; Ojosipe, B. A. *J. Am. Chem. Soc.* **1975**, 97, 5939; (d) Trost, B. M.; Seoane, P. R. *J. Am. Chem. Soc.* **1987**, 109, 615; (e) Machiguchi, T.; Hasegawa, T.; Ishii, Y.; Yamabe, S.; Minato, T. *J. Am. Chem. Soc.* **1993**, 115, 11536; (f) Nair, V.; Poonoth, M.; Vellalath, S.; Suresh, E.; Thirumalai, R. *J. Org. Chem.* **2006**, 71, 8964; (g) Trost, B. M.; McDougall, P. J.; Hartmann, O.; Wathen, P. T. *J. Am. Chem. Soc.* **2008**, 130, 14960; (h) Li, P.; Yamamoto, H. *J. Am. Chem. Soc.* **2009**, 131, 16628; (i) Xie, M.; Liu, X.; Wu, X.; Cai, Y.; Lin, L.; Feng, X. *Angew. Chem., Int. Ed.* **2013**, 52, 5604; (j) Liu, H.; Wu, Y.; Zhao, Y.; Li, Z.; Zhang, L.; Yang, W.; Jiang, H.; Jing, C.; Yu, H.; Wang, B.; Xiao, Y.; Guo, H. *J. Am. Chem. Soc.* **2014**, 136, 2625; (k) Teng, H.-L.; Yao, L.; Wang, C.-J. *J. Am. Chem. Soc.* **2014**, 136, 4075.
- (a) Pellissier, H. *Adv. Synth. Catal.* **2011**, 353, 189; (b) Ylijoki, K. E. O.; Stryker, J. M. *Chem. Rev.* **2013**, 113, 2244.
- (a) Shu, X.-Z.; Huang, S.; Shu, D.; Guzei, I. A.; Tang, W. *Angew. Chem., Int. Ed.* **2011**, 50, 8153; (b) Shu, X.-Z.; Schienebeck, C. M.; Song, W.; Guzei, I. A.; Tang, W. *Angew. Chem., Int. Ed.* **2013**, 52, 13601.
- Shu, X.-Z.; Li, X.; Shu, D.; Huang, S.; Schienebeck, C. M.; Zhou, X.; Robichaux, P. J.; Tang, W. *J. Am. Chem. Soc.* **2012**, 134, 5211.
- Schienebeck, C. M.; Li, X.; Shu, X.-Z.; Tang, W. *Pure Appl. Chem.* **2014**, 86, 409.
- Schienebeck, C. M.; Song, W.; Smits, A. M.; Tang, W. *Synthesis* **2015**, 47, 1076.
- Bychkova, N. A.; Zotchik, N. V.; Motorina, Z. N.; Rubtsov, I. A. *Zh. Obshch. Khim.* **1985**, 55, 1111.
- Kato, M.; Yamamoto, S.; Nomura, S.; Miwa, T. *Bull. Chem. Soc. Jpn.* **1990**, 63, 64.